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The Burkholderia cepacia complex (Bcc) is a group of Gram-negative bacteria that are ubiq-
uitous in the environment and have emerged as opportunistic pathogens in immunocom-
promised patients. The primary patient populations infected with Bcc include individuals
with cystic ﬁbrosis (CF), as well as those with chronic granulomatous disease (CGD).While
Bcc infection in CF is better characterized than in CGD, these two genetic diseases are not
obviously similar and it is currently unknown if there is any commonality in host immune
defects that is responsible for the susceptibility to Bcc. CF is caused by mutations in the
CF transmembrane conductance regulator, resulting in manifestations in various organ
systems, however the major cause of morbidity and mortality is currently due to bacte-
rial respiratory infections. CGD, on the other hand, is a genetic disorder that is caused
by defects in phagocyte NADPH oxidase. Because of the defect in CGD, phagocytes in
these patients are unable to produce reactive oxygen species, which results in increased
susceptibility to bacterial and fungal infections. Despite this signiﬁcant defect in microbial
clearance, the spectrumof pathogens frequently implicated in infections in CGD is relatively
narrow and includes some bacterial species that are considered almost pathognomonic for
this disorder. Very little is known about the cause of the speciﬁc susceptibility to Bcc over
other potential pathogens more prevalent in the environment, and a better understanding
of speciﬁc mechanisms required for bacterial virulence has become a high priority. This
review will summarize both the current knowledge and future directions related to Bcc
virulence in immunocompromised individuals with a focus on the roles of bacterial factors
and neutrophil defects in pathogenesis.
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INTRODUCTION
The Burkholderia cepacia complex (Bcc) is a group of Gram-
negative bacilli that have emerged over the past 30 years as
opportunistic pathogens in immunocompromised populations,
speciﬁcally cystic ﬁbrosis (CF) and chronic granulomatous dis-
ease (CGD). Bcc has recently been recognized as an emerging
nosocomial pathogen in patients without CF and CGD, and its
spread in the hospital setting has been associated with cross-
transmission, frequent pulmonary procedures, and central venous
access (Bressler et al., 2007). This complex of at least 17 distinct
species was ﬁrst identiﬁed as a plant pathogen in 1950s and was
shown to be the causative agent of onion rot (Burkholder, 1950;
Vanlaere et al., 2009; Lipuma, 2010). Bcc is also present in many
non-pathogenic, ecologically beneﬁcial relationships with plants,
where it can be advantageous through the production of antimi-
crobial compounds, degradation of contaminants, and ﬁxation of
nitrogen (Mahenthiralingam et al., 2005; Lipuma, 2010).
Since B. cenocepacia and B. multivorans are the two most
prevalent species in Bcc infections of both CGD and CF patients
(Reik et al., 2005; Bressler et al., 2007), most investigations into
the mechanisms of virulence have focused on these two species.
Although we will attempt to more broadly apply these data to
Bcc, it is currently unknown whether the recognized virulence
factors always function similarly in all species of the complex dur-
ing their interactionswith the host innate immune system. It is also
unknown whether there are unique and distinct bacterial factors
that are required for disease in CGD versus CF, considering that
these two diseases do not share any signiﬁcant known immune
defects. Due to the speciﬁc sensitivity of these two patient popu-
lations to Bcc, there may be unrecognized commonalities in host
defects that allow for Bcc infection.
Bcc AS OPPORTUNISTIC PATHOGENS
Because Bcc infections are primarily associated with individuals
with CGD and CF, it is interesting to compare these two not
obviously related genetic diseases. Table 1 summarizes the dis-
ease manifestations and defects in phagocyte function associated
with CGD and CF.
Burkholderia cepacia (previously referred to as Pseudomonas
cepacia) was recognized as an important pathogen in CGD in
1975 (Bottone et al., 1975). Bcc is now the leading cause of
fatality from bacterial infections in CGD patients (Winkelstein
et al., 2000). CGD is a genetic disorder caused by the inactivation
of the phagocyte nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase complex. Because of this defect, some cells
(neutrophils,mononuclear cells,macrophages, and eosinophils) in
Frontiers in Cellular and Infection Microbiology www.frontiersin.org November 2011 | Volume 1 | Article 9 | 1
Porter and Goldberg PMN defects and Bcc pathogenesis
Table 1 | Comparison of disease presentation and phagocyte function in CGD and CF.
CGD CF
DISEASE PRESENTATION
Mutation NADPH oxidase CFTR
Prevalence 1/200,000 live births (US) 1/3,000 live births
Clinical presentation Recurrent bacterial and fungal infections, most commonly
pneumonia, infectious dermatitis, and recurrent/severe
abscess formation
Chronic and recurrent bacterial colonization and inﬂam-
mation of the lungs
Infections commonly associated Aspergillus, Burkholderia, Serratia, Staphylococcus Pseudomonas, Burkholderia, Staphylococcus,
Haemophilus
DEFECTS IN PHAGOCYTE FUNCTION
Chemotaxis Robust recruitment of PMNs to sites of inﬂammation,
despite potential effects of ROS defect on PMN chemotaxis
Increased presence of and reduced responsiveness
to PMN chemoattractants (leukotriene B4, IL-8), robust
recruitment of PMNs to CF lung
Phagocytosis No known defects High concentrations of neutrophil elastase present in
the CF lung cleave CXCR1, Fcγ receptors, and iC3b, as
well as lead to the loss of CD16 and CD14 expression
(Hayes et al., 2011). The loss of these receptors leads
to deceased complement-dependent phagocytosis
Oxidative killing Inability to produce ROS caused by defect/inability to
assemble functional NADPH oxidase complex (Johnston
et al., 1975)
No physical defects in ability to produce normal quanti-
ties of ROS, but the inﬂammatory CF lung environment
may contribute to any abnormal oxidative responses
Non-oxidative killing Decreased ﬂux of potassium ions into the phagolysosome,
lack of increase in pH, and lack of normal acidiﬁcation
(Zarember and Malech, 2011). The combination of these
factors leads to a decrease in the activity of antimicrobial
peptides and enzymes. No NET formation (Fuchs et al.,
2007)
Potential alteration in degranulation; greater levels of
primary granule components are secreted extracellu-
larly by CF PMNs than normal PMNs, possibly due to
effects on intracellular pH on signaling (Hayes et al.,
2011). No intrinsic defects in the ability to produce NETs
(Young et al., 2011)
CGDpatients are unable to produce reactive oxygen species (ROS),
which results in ineffective clearance of some pathogens. These
patients present with recurrent bacterial and fungal infections,
which is frequently accompanied by uncontrolled inﬂammation
and granuloma formation. The rate of incidence in the United
States is 1/200,000 live births, or at least 20 patients per year
(Holland, 2010).
Chronic granulomatous disease can be caused by mutations in
any of the four components of NADPH oxidase. Flavocytochrome
b558 is the catalytic center of the complex, and is a heterodimer
composed of p22phox and gp91phox. It is contained on the mem-
brane of speciﬁc granules and is incorporated into the phagosome
membrane upon fusion (Segal, 2005). It provides a channel for
electrons to be transferred through fromNADPH in the cytosol to
oxygen that is contained in the phagosome (Segal, 2005). The com-
plex also contains two cytosolic components: p67phox and p47phox
(Zarember andMalech, 2011). These cytoplasmic components are
essential for stabilizing ﬂavocytochrome b558 and facilitating the
transfer of electrons. A defect in any one of these four components
leads to inactivation of the complex and an inability to produce
ROS. X-linked recessive CGD is caused by defects in gp91phox.
Autosomal recessive CGD is caused by defects in p47phox, p67phox,
or p22phox.Approximately 65%of CGDcases areX-linked (defects
in gp91phox), 25% of cases are due to defects in p47phox, and the
rest are split evenly between defects in p67phox and p22phox (Hol-
land, 2010). There are two other genetic disorders with similar
presentations to CGD that are not caused bymutations inNADPH
oxidase components. Inhibitory mutations in Rac or deﬁcien-
cies of glucose-6-phosphate dehydrogenase can also result in an
inability to produce ROS (Johnston, 2001).
Overall mortality for CGD patients is around 2–5% per year,
but morbidity remains a major issue for these patients and their
families, as most patients have at least one severe infection every
3–4 years (Winkelstein et al., 2000; Marciano et al., 2004). In the
initial cases of CGD diagnosed between 1957 and 1976, Staphy-
lococcus was the most common infectious agent, followed by the
common enteric pathogens Klebsiella species and Escherichia coli
(Johnston, 2001). Now Aspergillus species are the most common
causative infectious agents, followed by Bcc and Staphylococcus
aureus (Winkelstein et al., 2000). The most common presenta-
tions of infection include pneumonia, infectious dermatitis, and
recurrent/severe abscess formation beneath the skin and in organs
(Winkelstein et al., 2000). Other symptoms have been described
that are not caused directly by infection, including enteritis/colitis,
discoid lupus, and chorioretinitis (Goldblatt et al., 1999; Segal
et al., 2000; Winkelstein et al., 2000). The treatment regimen for
these patients includes interferon-γ, antibacterial prophylaxis, and
antifungal prophylaxis. Prophylactic treatment usually includes
trimethoprim–sulfamethoxazole and itraconazole (Seger, 2008).
Bone marrow transplantation can cure the disease if a histocom-
patible donor is available,which is not an option formost patients.
As with othermonogenetic diseases, gene therapy has the potential
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to be an effective curative treatment for CGD, however, to date,
clinical trials have not been successful. The promise and problems
associated with this approach have been recently reviewed (Grez
et al., 2011).
Cystic ﬁbrosis is caused bymutations in the CF transmembrane
conductance regulator (CFTR), which functions as an ion chan-
nel. This defect results in the accumulation of mucus on epithelial
surfaces, which contributes to ineffective mucociliary clearance
in the lungs. CF is one of the most common inherited genetic
diseases in the world with an annual frequency of approximately
1/3,000 live births (Hayes et al., 2011). In fact, one out of every
25 Caucasians is a heterozygous carrier of a mutated CFTR gene
(Sheppard and Nicholson, 2002). The airway in CF patients is
chronically colonizedwith potentially pathogenic bacteria, speciﬁ-
cally Pseudomonas aeruginosa, S. aureus, andHaemophilus inﬂuen-
zae. Colonization and frequent infection of the CF airway leads
to an excessive neutrophil (polymorphonuclear leukocyte, PMN)
driven inﬂammatory response,which results in host tissue damage
(McElvaney et al., 1992; Birrer et al., 1994). These patients experi-
ence recurrent respiratory infections and chronic lung inﬂamma-
tion that eventually culminates in respiratory failure (Dinwiddie,
2000). Pulmonary inﬂammation in CF is associated with high
levels of inﬂammatory cytokines (IL-8, IL-6, TNF-alpha, and
leukotriene B4), reduced levels of anti-inﬂammatory cytokines
and antiproteases, and a rapid and substantial inﬂux of PMNs
(Rowe et al., 2005).
Burkholderia cepacia complex infections in both the CGD and
CF patient populations initially present as a respiratory tract infec-
tion. An interesting distinction between infections in these two
patient populations is the clinical presentation of this infection. In
CF, pulmonary infection with Bcc generally causes endobronchial
disease, and diagnosis is made by identiﬁcation of bacteria in the
sputum. InCGD,Bcc lung infection results in a pneumonic process
associated with nodular inﬁltrates and diagnosis requires isola-
tion following lung biopsy. Antibiotic treatment is generally able
to clear Bcc in CGD, although recurrent re-infections do occur.
In CF, Bcc infections are usually seen in older patients that are
already chronically colonized with other CF pathogens, notably P.
aeruginosa (Sheppard andNicholson,2002).According to the 2009
Cystic Fibrosis Foundation Registry Report, about 2.7% of CF
patients are infected with Bcc, and these infections are associated
with earlier fatality thannon-Bcc-infectedpatients. Potentially due
to the chronic nature of Bcc infections in CF and the sustained
presence of the microbial community in the form of bioﬁlms
in the CF lung, Bcc isolates associated with CF show a higher
degree of antibiotic resistance than Bcc isolates from CGD infec-
tions (Greenberg et al., 2009). Bcc infections in CF patients can
result in a severe, necrotizing pneumonia, referred to as “cepacia
syndrome,” that is not observed in Bcc infections in CGD patients.
However, Bcc infections in CGD patients can become invasive and
result in septicemia.
Chronic granulomatous disease and CF are both rare genetic
diseases and, while infections by Bcc are prominent in these
populations, Bcc infections are still relatively infrequent. Stud-
ies investigating Bcc virulence in CGD and CF aim to decrease
morbidity and mortality in these patient populations, but they
can also increase our understanding of how healthy individuals
are able to ﬁght off these rare infections. Since Bcc infections are
very uncommon in immunocompetent individuals, the normal
host immune response must be able to efﬁciently remove these
pathogens, and the immune response or environment in CGD
and CF, as well as other immunocompromised patients, would
appear to be defective in this clearance. It is the investigation into
the distinction between these normal and susceptible hosts that
gives insight into normal and defective immune function in bac-
terial infections. Previous studies investigating CGD and other
rare genetic diseases have contributed greatly to knowledge in the
ﬁeld on normal phagocyte function and bacteria–phagocyte inter-
actions (Quie et al., 1967; Root et al., 1972; Lekstrom-Himes and
Gallin, 2000). A better understanding of the infectious processes
in patients with rare genetic defects in phagocyte function con-
tributes to current knowledge on how normal, healthy individuals
resist infections.
FUNCTIONS OF NORMAL PMNs AND DEFECTS IN CGD AND
CF PATIENTS
Chronic granulomatous disease manifests as a defect in all phago-
cytes normally capable of producing ROS. Macrophages and
PMNs are normally the focus of study of CGD host phagocyte–
pathogen interactions because of their essential roles as profes-
sional phagocytes. A recent review by Saldias and Valvano (2009)
has summarized the current literature on the interactions between
Bcc and macrophages, thus here we will focus speciﬁcally on Bcc
interactionswithPMNs.Bcc infections are characterizedby a rapid
and robust recruitment of PMNs to the site of infection. Normal
PMNshave the ability tophagocytose andkill bacteria via oxidative
and non-oxidative mechanisms, but CGD PMNs are only capable
of utilizing non-oxidative killing mechanisms, leading to ineffec-
tive clearance of some pathogens. Because of the essential role of
PMNs in normal host responses to bacteria and the substantial
contribution of defective PMN function in CGD to pathogenesis,
this review will focus on the defects associated with CGD PMNs
and will provide comparison with potential defects in CF PMN
function.
Polymorphonuclear leukocytes are highly motile phagocytes
that comprise the ﬁrst line of defense of the innate immune system
against bacteria and play a crucial role in host defense in the lung.
Four percent of the adult body mass is devoted to the production
of PMNs, and as a result, PMNs are the most common nucleated
cell in blood. Although PMNs are terminally differentiated once
they leave bone marrow, they are still able to act autonomously
as wandering phagocytes in all tissues, requiring highly speciﬁc
and specialized responses (Zarember andMalech, 2011). They kill
bacteria by fusing granules containing antimicrobial compounds
with phagocytic compartments containing bacteria. These gran-
ules can also fuse with the plasma membrane to kill extracellular
bacteria.
There are three types of granules that PMNs synthesize,
and these different granule types contain molecules with dif-
ferent antimicrobial activities that often work synergistically to
kill microbes once fused with the phagosome. Granules con-
tain components that kill bacteria through both oxidative and
non-oxidative mechanisms. Azurophil or primary granules con-
tain myeloperoxidase, three neutral proteinases (cathepsin G,
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elastase, and proteinase 3), bactericidal permeability-increasing
protein (BPI), and defensins. Speciﬁc or secondary granules con-
tain lactoferrin, transcobalamin II, lysozyme, gelatinase-associated
lipocalin, and ﬂavocytochrome b558. Gelatinase or tertiary gran-
ules are classiﬁed by the presence of gelatinase but not lactoferrin
and can contain any of the other components in speciﬁc gran-
ules. The matrix in granules contains negatively charged sulfated
proteoglycans that sequester antimicrobial components until the
granule is fused with the phagosome (Borregaard and Cowland,
1997; Segal, 2005).
Oxidative killing relies on the generation of ROS, primarily
through NADPH oxidase. Electron transfer to oxygen through
NADPH oxidase generates superoxide (O−2 ) in the phagosome.
Superoxide is rapidly degraded into hydrogen peroxide (H2O2) by
superoxide dismutase. Hydrogen peroxide can readily cross bac-
terial membranes and cause intracellular damage. CGD PMNs
are defective in their ability to assemble functional NADPH oxi-
dase complexes and therefore are unable to utilize oxidative killing
mechanisms.
In addition to oxidative killing mechanisms, normal PMNs can
also use non-oxidative killing,which includes interactions between
cationic regions of the granule proteins and the negatively charged
bacterial membrane, as well as bacterial degradation by granule
proteases. Examples of cationic peptides and proteins involved in
non-oxidative killing of bacteria are BPI, LL-37, defensins, and
azurocidin. These cationic granule peptides and proteins bind to
and accumulate on the bacterial surface, leading tomembrane per-
meabilization and osmotic lysis. These components are extremely
important in non-oxidative killing of Gram-negative pathogens by
PMNs (Hancock andDiamond,2000).Granules also containother
components that possess different antimicrobial activities. Serine
proteases degrade phagocytosed bacteria (Wiedow and Meyer-
Hoffert, 2005). Lactoferrin sequesters iron away from pathogens,
but also possesses direct antimicrobial activity (Ellison and Giehl,
1991). Many of the factors that function in non-oxidative killing
strategies act synergistically or depend on each other for full activ-
ity after fusion or exocytosis. The lack of functional NADPH
oxidase in CGD results in the reduced ﬂux of potassium ions
into the phagolysosome (Zarember andMalech, 2011). This inﬂux
plays a role in the release of cationic proteins from the matrix,
and because of this CGD PMNs may also exhibit defects in non-
oxidative killing. In CGD PMNs, the phagolysosome additionally
does not increase pH and does not acidify as profoundly, which
also has negative effects on the activity of antimicrobial peptides
and enzymes (Dri et al., 2002).
Normal PMNs also use neutrophil extracellular traps (NETs)
as a mechanism to kill extracellular microbes. These NETs are
composed of PMN chromatin coated in granule components that
have been expelled from the cell. The chromatin binds extracel-
lular bacteria and fungi, trapping them in close contact with high
concentrations of antimicrobial granule contents. NET formation
is dependent on the generation of ROS by NADPH oxidase, and
therefore CGD PMNs are also deﬁcient in their ability to produce
NETs (Fuchs et al., 2007). It has been shown that this defect also
contributes to the inability of CGD PMNs to kill pathogens com-
monly associatedwith infections inCGD, speciﬁcally S. aureus and
Aspergillus species (Brinkmann et al., 2004; Bianchi et al., 2009).
Most prior research has focused on the lung epithelial cell
defects in CF (Conese and Assael, 2001; Machen, 2006). How-
ever more recently, there has been an emphasis in the ﬁeld on
defective immune cell function in the CF lung environment, par-
ticularly on potential defects in PMN function. These studies may
assist in bridging the gap in understanding the speciﬁc suscepti-
bilities of these two patient populations to Bcc infections. Defects
in CF PMN function could contribute to ineffective clearance of
lung pathogens in the presence of zealous PMN recruitment and
inﬂammation (Hayes et al., 2011). It is alreadywell established that
PMN necrosis and release of proteolytic enzymes contribute sig-
niﬁcantly to the tissue damage in the CF lung. It has been shown
that PMNs can become trapped in bacterial bioﬁlms in the CF
lung and undergo necrosis; after necrosis, their biomass, NETs,
and intracellular leakage can contribute bioﬁlm formation and
lung injury (Jesaitis et al., 2003; Brinkmann et al., 2004; Walker
et al., 2005). CF PMNs display excessive and prolonged superox-
ide production when stimulated, are constitutively primed (likely
via the presence of IL-8, TNF-alpha, and P. aeruginosa alginate
in the CF airway), and are unresponsive to anti-inﬂammatory sig-
nals through IL-10 (Pedersen et al., 1990;Koller et al., 1995;Taggart
et al., 2000). Another observed potential defect is an alteration in
degranulation; greater levels of primary granule components are
secreted extracellularly by CF PMNs than by normal PMNs, pos-
sibly due to effects of intracellular pH on signaling (Koller et al.,
1995; Coakley et al., 2000, 2002; Taggart et al., 2000). This release
of toxic granule contents contributes to the extensive lung damage
characteristic of CF. The absence of CFTR has also been shown
to have direct effects on PMN function. The addition of chloride
ion to hydrogen peroxide to produce hypochlorous acid (HOCl)
throughmyeloperoxidase is anotherROS-dependent killingmech-
anism, and CF PMNs display a decreased ability to chlorinate
bacteria and a decreased ability to kill P. aeruginosa that is exac-
erbated by a chloride-deﬁcient microenvironment (Painter et al.,
2006, 2008).
There are also indications that the environment in the CF lung
may signiﬁcantly impair PMN function. High concentrations of
neutrophil elastase present in the CF lung cleave CXCR1, Fcγ
receptors, and iC3b, as well as lead to the loss of CD16 and CD14
expression (Tosi et al., 1990; Birrer et al., 1994; Alexis et al., 2006;
Hartl et al., 2007; Tirouvanziam et al., 2008). The loss of these
receptors leads to deceased complement-dependent phagocyto-
sis. Hypersalinity of the airway surface ﬂuid has been shown to
inhibit the killing actions of epithelial cells in the CF lung through
inactivation of β-defensin-1 and potentially other antimicrobials,
although these ﬁndings are considered somewhat controversial in
the CF ﬁeld (Smith et al., 1996; Goldman et al., 1997; Krouse,
2001). Peripheral PMNs isolated from CF patients show compa-
rable NET formation to normal PMNs, but there is also evidence
that PMNs in the CF lung environment display increasedNET for-
mation that contributes to the pulmonary obstruction typical in
CF (Marcos et al., 2010; Young et al., 2011). Further investigation
into defective phagocyte function in CF could provide insight into
links between the susceptibilities of both these patient populations
to Bcc infections.
Although resident and migrating phagocytes play an essential
role in bacterial clearance in the airway, there are other important
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components of the host defense at the mucosal airway surface.
The airway epithelium protects the host from infection at the
interface with the environment, where it is constantly exposed
and bombarded with microbes. Epithelial cells produce cytokines,
chemokines, and antimicrobial peptides, either constitutively or
upon stimulation with microbial products (Bals and Hiemstra,
2004). Examples of antimicrobial products produced by airway
epithelial cells include β-defensins, LL-37, and lactoferrin (Bals
and Hiemstra, 2004). Dual oxidases (Duox) are also expressed
by epithelial cells in the airways and produce hydrogen peroxide,
which contributes to antimicrobial activities through the lactoper-
oxidase system (Geiszt et al., 2003). This theoretically allows for
partial reconstitution of ROS production in the lung in response
to bacterial infection, but interesting it has been shown that Bcc
does not stimulate hydrogen peroxide production by bronchial
epithelial cells through Duox (Rada and Leto, 2010).
MODELS USED TO ASSESS VIRULENCE OF Bcc IN CGD AND
CF
Many previous studies have focused on Bcc virulence in models
of CF, and these models have been well described in other reviews
(Scholte et al., 2004; Mahenthiralingam et al., 2005; Loutet and
Valvano, 2010). Therefore, this section will focus on describing
models of CGD and their potential for use in studies of Bcc vir-
ulence. Many in vitro and in vivo models of CGD are available,
and some of these models have been adapted to assess microbial
virulence in this patient population. There are two characterized,
commercially availablemousemodels of CGD. The ﬁrst is amodel
of X-linked CGD, which lacks the mouse equivalent of human
gp91phox (Pollock et al., 1995). This strain of mouse exhibits a
complete lack of functional protein, an inability to form a func-
tional NADPH oxidase complex, and phagocytes that are unable
to produce a respiratory burst. Bcc are virtually avirulent in wild-
type mouse strains but are able to cause lethal infections in mouse
models of CGD (Chiu et al., 2001; Sousa et al., 2007). Bcc CF
isolates have been tested in this model, and the infecting bacteria
multiplied ﬁve orders of magnitude in 3–6 days after intratracheal
infection. The infectedmice displayed neutrophil-dominated lung
inﬂammation and abscesses, sepsis, and eventual death, which
models a disease progression reﬂective of that observed in CGD
human hosts. Isogenic mutants in some known virulence factors
of B. cepacia and B. cenocepacia, in particular in quorum sensing
and exopolysaccharide production, as well as a panel of less viru-
lent isolates were also examined, and a loss or decrease in virulence
was observed (Sousa et al., 2007).
The autosomal recessive mousemodel of CGD lacks themouse
equivalent of p47phox, which is the complex component most
commonly associated with human cases of autosomal recessive
CGD. Characterization of this model showed a phenotype sim-
ilar to human CGD; these mice spontaneously developed severe
infections, usually by the same or related pathogens that are asso-
ciated with infections in human CGD hosts (Jackson et al., 1995).
Phagocytes from these animals display an inability to produce an
oxidative burst and are unable to kill S. aureus and other pathogens
characteristic of CGD (Jackson et al., 1995). This model has also
been used to study the virulence of Bcc in CGD. B. multivorans
clinical isolates from both CGD and CF patients were shown to
establish lethal infections when injected intraperitoneally, while
an environmental isolate was avirulent (Zelazny et al., 2009).
Mouse models allow analysis of Bcc virulence in a CGD host,
but additional approaches are necessary to directly investigate Bcc
interactions with host phagocytes. Both cell lines and primary cells
have been used in assessment of bacterial virulence in interactions
with CGD phagocytes. PMNs and macrophages can be derived
from CGD patients, when available, or from CGD animals (Mor-
genstern et al., 1997; Kaneda et al., 1999; Zelazny et al., 2009).
Because these cells are isolated directly from patients or animals
with CGD, these cells most closely replicate the CGD defect, but
unfortunately are unable to be genetically modiﬁed or adequately
controlled experimentally. Also, the use of primary cells adds an
additional level of variation to experiments due to donor-speciﬁc
genetic and environmental factors. Cell lines that are genetically
modiﬁed to lack functional NADPH oxidase proteins have also
been constructed. PBL-985, a humanmyeloid leukemia cell line, is
deﬁcient in gp91phox and can be differentiated into monocytes or
granulocytes (Zhen et al., 1993). These cells can be further genet-
ically modiﬁed and lack the donor variability of primary cells.
Unfortunately, PMNs are terminally differentiated cells, and pre-
cursor immortal cell lines must be differentiated in vitro into a
PMN-like state. In a related promyelocytic cell line, HL-60, it has
been demonstrated that in vitro differentiation from the promye-
locytic stage results in an inability to synthesize secondary and
tertiary granules (Le Cabec et al., 1997). Therefore, these precur-
sor cell lines lack the full array of antimicrobial activities associated
withmature, terminal PMNs. There are also variants of the J774.16
murine macrophage cell line that are deﬁcient in gp91phox, and
do not need to be differentiated (Goldberg et al., 1990). These
immortal macrophage lines can be used to broadly study phago-
cyte interactions but are unable to utilize the full repertoire of
killing mechanisms employed by PMNs.
Normal cell lines and primary cells can also be treated with
inhibitors of NADPH oxidase function to create a CGD pheno-
type. Diphenyleneiodonium (DPI) is the most commonly used
inhibitor and acts on ﬂavoproteins, such as ﬂavocytochrome b558
of NADPH oxidase. An electron is extracted from ﬂavin adenine
dinucleotide (FAD) by DPI to form a radical, which is then added
back to protein groups in or near the active site of the ﬂavoprotein
to form covalent, phenylated adducts. Studies have also shown that
DPI can also act on and inhibit nitric oxide synthase and xanthine
oxidase (Riganti et al., 2004), while anaerobic killing, phagocyto-
sis, and motility are not signiﬁcantly affected by DPI-treatment
(Ellis et al., 1988). There is a slight decrease in degranulation of
azurophilic and speciﬁc granules after DPI-treatment, which is
similar to what has been observed in PMNs isolated from CGD
patients (Ellis et al., 1988). Another well-studied NADPH oxi-
dase inhibitor is apocynin (4-hydroxy-3-methoxyacetophenone,
also known as acetovanillone), which is a methoxy-substituted
catechol that inhibits superoxide production by phagocytes while
not affecting phagocytosis. It likely inhibits complex assembly by
blocking sulfhydryl groups (Vejrazka et al., 2005). Although use
of these inhibitors produces a CGD phenotype and creates an
in vitro system amenable to controlled experimentation, the cells
may exhibit additional defects due to non-speciﬁc action of these
inhibitors or may not manifest completely the defects of CGD
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phagocytes. Also, in vitro experimentation with either primary
cells or immortal cell lines can only be used to assess virulence
factors that directly interact with host cells in comparison to fac-
tors that may indirectly affect cells through modulating the host
environment.
RESISTANCE OF Bcc TO KILLING BY PMNs
Burkholderia cepacia complex is a very diverse group of pathogens,
both genetically and phenotypically. Studies have shown remark-
able differences in virulence between clinical isolates and environ-
mental isolates of Bcc, and even clinical strains of the same species
have been observed to have varying virulence in vitro and inmouse
models. In the context of Bcc infections inCF (Loutet andValvano,
2010), factors have been shown to have direct effects on interac-
tions with host innate immune cells. Both Figure 1 and Table 2
illustrate the contribution of Bcc factors to bacterial survival in
interactions with phagocytes. Most of the factors described in this
review have been investigated mainly in models of CF, but these
factors may have broad roles for protection from host phagocyte
killing and are likely also important in Bcc survival in interactions
with CGD PMNs.
B. cenocepacia has been shown to be readily ingested by normal
PMNs and phagocytosis is associatedwith a robust oxidative burst.
In PMN bactericidal assays, Bcc is killed by normal PMNs but is
able to persist when incubated with CGD PMNs (Zelazny et al.,
2009; Greenberg et al., 2010). Similarly B. cenocepacia has been
found to induce PMN apoptosis, an effect dependent on viable
bacteria. CGD PMNs were also equally apoptotic in comparison
to normal PMNs after phagocytosis of B. cenocepacia, but B. ceno-
cepacia also induced PMN necrosis in a subset of CGD PMNs,
which could contribute to increased virulence in this population.
This was true in both primary CGD PMNs and PMNs treated
with DPI (Bylund et al., 2005). Another study found that a CGD
clinical isolate of B. multivorans showed a higher association with
CGD PMNs than with PMNs from normal, healthy donors, which
suggests an additional distinction between the interactions of Bcc
with normal and CGD PMNs (Zelazny et al., 2009).
DEFENSES AGAINST HOST OXIDATIVE KILLING
In the course of an infection, successful pathogens must evade
the innate immune system in order to persist. Because of the
prevalence of Bcc as CGD pathogens, oxidative killing mecha-
nisms by host phagocytes, speciﬁcally neutrophils, are thought to
be essential for Bcc clearance in healthy individuals. Superoxide
dismutases and catalases protect bacteria from oxidative damage
during normal respiration and in interactions with the host innate
immune response. Bcc has been shown to be resistant to con-
centrations of ROS in vitro that are equivalent to an oxidative
burst and this is due to periplasmic superoxide dismutase (Sod),
catalase-peroxidases (Kat), and an antioxidant melanin-like pig-
ment (Lefebre andValvano, 2001; Saldias andValvano, 2009). Both
catalase and superoxide dismutase are universal mechanisms of
bacterial resistance to host oxidative killing. A pigment produced
by B. cenocepacia C5424 has been studied, and the absence of the
pigment in a strain mutated in hppD (4-hydroxyphenylpyruvate
dioxygenase) was shown to lead to an increase in sensitivity to
extracellular superoxide and hydrogen peroxide in in vitro bacter-
ial viability assays (Keith et al., 2007). This study also showed that
themutant co-localized to a higher extent than thewild-type strain
with more degradative compartments in macrophages, and that
this co-localization was dependent on NADPH oxidase activity.
This ﬁnding suggested that wild-type bacteria that are able to pro-
duce the melanin-like pigment are more protected from oxidative
killing in the phagosome, and that mutant bacteria that are unable
FIGURE 1 | Burkholderia cepacia complex virulence factors important for survival in interactions with host phagocytes. Representation of known
virulence factors utilized by members of Bcc in order to persist when confronting host phagocytes.The description and evidence in support of the roles of these
factors is described in the text.
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Table 2 | Burkholderia cepacia complex virulence factors involved in interactions with host phagocytes.
Role Reference
OXIDATIVE KILLING
Catalase (KatA, KatB, and KatG) Catalyzes degradation of hydrogen peroxide into water and oxygen Lefebre et al. (2005),
Charalabous et al. (2007)
Superoxide dismutase (SodB and SodC) Catalyzes degradation of superoxide into hydrogen peroxide Keith andValvano (2007)
Melanin-like pigment Antioxidant pigment, protects against host oxidative stress Keith et al. (2007)
Cepacian exopolysaccharide Scavenges ROS, inhibits PMN chemotaxis Bylund et al. (2006)
NON-OXIDATIVE KILLING
Zinc metalloproteases (ZmpA and ZmpB) Proteolytically degrades host antimicrobials (examples: LL-37, β-defensin-1, and
secretory leukocyte inhibitor)
Kooi et al. (2006), Kooi
and Sokol (2009)
Lipopolysaccharide core Confers resistance to polymyxin B and host antimicrobial peptides Loutet et al. (2006)
RpoE (σE) Alternative sigma factor that regulates genes required for resistance to polymyxin
B, which likely contribute to resistance to host non-oxidative killing
Loutet et al. (2011)
INTRACELLULAR SURVIVAL
RpoN (σN) Alternative sigma factor that regulates genes required for delay of
phagolysosomal fusion in macrophages, traditionally involved in gene regulation
in nitrogen-limited environmental conditions
Saldias et al. (2008)
RpoE (σE) Alternative sigma factor that is required for delay of phagolysosomal fusion in
macrophages, traditionally involved in gene regulation in response to
extracytoplasmic/heat stress
Flannagan and Valvano
(2008)
Type IV secretion system Required for intracellular survival and replication in macrophages, may play a role
in normal endocytic processing
Sajjan et al. (2008)
Type VI secretion system Involved in actin rearrangements in macrophages Aubert et al. (2008)
to produce the pigment are associated with a loss of bacterial
viability inside the phagosome and an inability to delay progres-
sion to a more degradative compartment. Thus, the melanin-like
antioxidant pigment produced by B. cenocepacia has been shown
to be protective against host oxidative killing (Keith et al., 2007).
However not all strains of Bcc isolated from patients produce this
pigment, suggesting that additional mechanisms of resisting host
oxidative killing must exist.
Exopolysaccharides are bacterial virulence factors that have
roles in evasion of host defenses, adhesion, and resistance to
antimicrobials. Bcc produces at least four different exopolysac-
charides, and the predominant exopolysaccharide is the heptasac-
charide cepacian (Vinion-Dubiel and Goldberg, 2003; Zlosnik and
Speert, 2010). Not all Bcc isolates make cepacian, but most clinical
isolates do produce exopolysaccharide (Zlosnik and Speert, 2010).
Cepacian produced by B. cenocepacia has been shown to scavenge
ROS and inhibit neutrophil chemotaxis in in vitromigration assays
(Bylund et al., 2006). Mutants that are unable to produce cepa-
cian are less virulent than wild-type, cepacian-producing strains
in a gp91phox−/− mouse model of CGD, which suggests that this
exopolysaccharide is potentially an important bacterial factor for
virulence in CGD (Sousa et al., 2007).
DEFENSES AGAINST HOST NON-OXIDATIVE KILLING
Burkholderia cepacia complex possesses tools to combat non-
oxidative killingmechanisms,and these factors likely play an essen-
tial role in bacterial pathogenesis in CGD hosts that are defective
in their ability to kill bacteria through oxidative killing mecha-
nisms. Zinc metalloproteases are commonly utilized by bacteria
to proteolytically degrade host antimicrobials. B. cenocepacia zinc
metalloproteases ZmpA and ZmpB have been shown to act in
resisting bacterial killing by host antimicrobial peptides in in vitro
bacterial viability assays (Kooi and Sokol, 2009). ZmpB cleaves β-
defensin-1, ZmpA cleaves LL-37, and both enzymes cleave elaﬁn
and secretory leukocyte inhibitor. All of these targets are com-
ponents of the innate immune response to bacteria. Mutants in
both zmpA and zmpB have been tested in a rat agar bead model,
which is commonly used for assessing virulence of pathogens that
chronically infect CF patients. Both mutant strains were able to
persist and were present in the lung 14 days after infection, but
theywere less virulent than thewild-type strain. The zmpA mutant
was characterized by a reduction in bacterial load in comparison
to the wild-type strain, and the zmpB induced less lung tissue
inﬂammation (Kooi et al., 2006). This indicates that ZmpA and
ZmpB are required for full virulence but are not required for bac-
terial survival in this model. It would be interesting to evaluate
these mutants in a mouse model of CGD, since such an acute
model of infection could directly assess the importance of these
zinc metalloproteases to infection.
Lipopolysaccharide (LPS) is dually important both in targeting
of and protection from non-oxidative killing. LPS is a major com-
ponent of Gram-negative membrane and is composed of lipid
A, core oligosaccharides, and O-antigen. The negative charge of
lipid A is an important binding target for cationic antimicrobial
peptides. The lipid A of Bcc contains Kdo (3-deoxy-d-manno-
oct-2-ulosinic acid), Ko monosaccharide (d-glycero-d-talo-oct-
ulosonic acid), and Ara4N (4-amino-4-deoxy-l-arabinose; Silipo
et al., 2005, 2007). Substitution of Ara4N on the lipid A and inner
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core oligosaccharide is protective against cationic antimicrobials,
and synthesis of Ara4N is essential in B. cenocepacia for survival
(Ortega et al., 2007). Inner core oligosaccharides are required for
in vitro resistance to antimicrobial peptides and survival in a rat
model of lung infection. Speciﬁcally, a deep rough mutant (lack-
ing bothO-antigen and the inner core) of B. cenocepacia wasmore
sensitive to killing by polymyxin B,melittin, and HNP-1 in in vitro
bacterial viability assays (Loutet et al., 2006).
In a signature-taggedmutagenesis screenof B. cenocepacia K56-
2 in the rat agar bead model of chronic infection, several clones
were identiﬁed as being avirulent that contained insertions in
the genetic region responsible for O-antigen synthesis, indicating
that under these conditions O-antigen was essential for virulence
(Hunt et al., 2004). Interestingly, clinical isolates have been isolated
with either an LPS-rough (with no O-antigen) or an LPS-smooth
(with O-antigen) phenotype, indicating that O-antigen may not
be required for virulence in all species of the complex under all
conditions. For example, one of the best characterizedB. cenocepa-
cia isolates, the ET-12 lineage CF isolate J2315, which displays an
LPS-rough phenotype. O-antigen has been shown to be essential
for serum resistance but not in resistance to host antimicrobials
(Ortega et al., 2005).
In addition to factors that have been recognized to act directly to
protect against host defenses,genetic regulators can also contribute
to virulence. The alternative sigma factor RpoE, a transcriptional
regulator, has been shown to be required for lysosomal fusion
delay, growth under high osmolarity, and growth under high
temperature (Flannagan and Valvano, 2008). RpoE has also been
shown to play a role in resistance to polymyxin B in in vitro bac-
terial viability assays, which suggests that expression of RpoE may
protect thebacteria fromnon-oxidative killing aswell (Loutet et al.,
2011). Collectively, these two studies do implicate that regulation
by RpoE is important for Bcc virulence, but the RpoE regulon has
yet to be reported.
Since normal,healthy individuals do not typically contract clin-
ical Bcc infections, the virulence associated with each of these
factors likely relies partially on host susceptibility and bacterial
factors, which may differ between these two genetic disorders.
Although the virulence factors studied inCF likely also play impor-
tant roles in Bcc pathogenesis in CGD, this is by no means a com-
prehensive list and research is currently being conducted to learn
more about speciﬁc roles of both these molecules as well as cur-
rently unrecognized factors using models for assessing virulence
in CGD.
CONCLUDING REMARKS AND FUTURE DIRECTIONS
Despite the extensive amount of focus and new insight into Bcc
virulence obtained in the past decade, there is still much to learn.
Bcc is a very diverse group comprising of at least 17 distinct species,
and the majority of studies have focused on only the most preva-
lent three species: B. cenocepacia, B. multivorans, and B. cepacia.
Also, many clinical strains and available isogenic mutants within
these species have only been investigated in subsets of the models
available to assess virulence in either CGD or CF. A more com-
prehensive view of the virulence of this complex will be obtained
through future studies characterizing the similarities and differ-
ences between each species and the role of each virulence factor
in many models. It is already recognized that clinical isolates from
the same species (example: B. cenocepacia J2315 and K56-2) dis-
play different virulence phenotypes, and differences between these
related isolates could be characterized. In addition, most studies
have focused on Bcc virulence in the context of CF. As presented in
this review,many of these studies have contributed knowledge that
can be applied to potential host–pathogen interactions in CGD.
Further characterization of known virulence factors in models of
CGD and high-throughput genetic screens to identify virulence
factors that are essential speciﬁcally in CGD will generate a more
complete understanding of Bcc pathogenesis in CGD. Also, as pre-
viously mentioned, there is no clear link between the immune
defects in CF and CGD, and therefore the progression of disease
and factors required coulddiffer greatly between infections in these
two patient populations.
A majority of the work investigating Bcc–host phagocyte inter-
actions up to now has focused on macrophages, mainly due to the
availability of immortal cell lines. Due to the large inﬂux of PMNs
to the site of infection in both CF and CGD, PMNs are playing
an extremely important role in pathogenesis. The bacterial killing
mechanisms used by PMNs are more numerous and varied than
that of macrophages, and the process of phagosomal maturation
also varies greatly between PMNs and macrophages. It is thought
that Bcc exists in an intracellular Bcc-containing vacuole (BcCV)
inmacrophages, but it is unknownwhether Bcc is able to persist in
a similar compartment in PMNs (Lamothe et al., 2007). It has been
shown that both the type IV and type VI secretion systems play a
role in interactions with macrophages and may be important for
intracellular survival, but it is unknown what their role is in inter-
actions with PMNs (Aubert et al., 2008; Sajjan et al., 2008). It has
been demonstrated that Bcc is ineffectively killed and cleared by
CGD PMNs (Zelazny et al., 2009; Greenberg et al., 2010), but it is
not clear whether the surviving Bcc are intracellular or associated
extracellularly with PMNs. This distinction is very important for
understanding the mechanism in which Bcc is able to persist in
this patient population.
Another avenue for future research is to identify mechanisms
of effective killing and clearance of Bcc in normal individuals.
Normal PMNs are able to effectively kill Bcc while CGD PMNs
are unable to do so. Because of the defect in oxidative killing in
CGD, this was suggestive of oxidative killing being important for
clearance by normal PMNs.However, in vitro studies have demon-
strated high resistance of Bcc to both oxidative and non-oxidative
killing mechanisms. There are also other defects in non-oxidative
killing associated with CGD PMNs, speciﬁcally in granule compo-
nent activation andNET formation. It could also be the synergistic
effects of all of these defects together that allow for persistence in
this patient population as well as in CF patients. These mecha-
nistic studies are difﬁcult in a terminally differentiated cell that
is not amenable to genetic manipulation but could be feasible
in vitro using puriﬁed components or in cell-based assays using
combinations of inhibitors.
A more broad implication of understanding Bcc pathogene-
sis in CGD is to search for commonalities in virulence strategies
employed by all CGD pathogens. Since the spectrum of potential
pathogens causing infections in this population is very narrow and
most infectious agents are opportunistic, theremay be very speciﬁc
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factors or strategies utilized by this group of microbes to cause
infections in CGD. Understanding these overarching themes of
resistance to killing in theCGDhost could lead to the development
of both preventative care and treatment options.
Since Bcc infections are typically restricted to patients with CF
orCGD, the comparison of the defects in these two genetic diseases
remains an interesting venue for future research. As previously
described in this review, Bcc infections in CF occur subsequent
to colonization with P. aeruginosa, and the presence of bacterial
bioﬁlms and the effect of these bioﬁlms on PMN function may
contribute to the ability of Bcc to persist in CF patients. A recent
study conﬁrmed the contribution of the CF lung environment
to susceptibility to Bcc by infecting wild-type, normally resistant
mice with B. cenocepacia and alginate from P. aeruginosa; in this
case the bacteria were able to persist and cause lung inﬂamma-
tion (Goldberg et al., 2011). It is also hypothesized that the CF
lung environment may result in defective PMN function through
anaerobic mucus-covered airways, high protease concentrations,
and high levels of inﬂammatory signals (Boucher, 2004; Hayes
et al., 2011). In addition to the lung environment, treatments for
CF may also impact PMN function. Macrolide therapy has been
shown to signiﬁcantly improve lung function inCF,but these drugs
also accelerate PMN apoptosis, inhibit ROS production by PMNs,
and inactivate neutrophil elastase (Aoshiba et al., 1995; Gorrini
et al., 2001; Shinkai and Rubin, 2005). The use of macrolides is
largely ineffective in treatment and prevention of Bcc, and its
effects on PMN function may actually contribute to the path-
ogenicity of Bcc in CF (Saiman et al., 2002). A more complete
understanding of PMN defects in CF, whether attributed to treat-
ment, the inﬂammatory environment, or the CFTR defect directly,
could ﬁnd a link between immune function in these two patient
populations and better deﬁne the requirements for Bcc virulence
in immunocompromised populations.
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